GHO Capital, the European specialist investor in healthcare, completed the investment in FairJourney Biologics, a provider of antibody discovery services to global biopharma, in a $55m deal. “We have chosen to partner with GHO not only for our shared vision but also our common values. With their recent track record of creating transatlantic leaders in the outsourced services space, significant global network and expertise in biologics we can take our proven business model to a new scale. We will deliver more services and capacity to our growing global client base with a continued focus on the quality, flexibility and speed of our service delivery,” Antonio Parada, FairJourney CEO.